Bristol Myers Squibb (BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc., in an all-cash transaction.
Regulatory News: Disclaimer: Intended for international media and investor audiences only. Ipsen (IPSEF) today announced the closing of the definitive merger agreement under which Ipsen (IPSEF) has acquired Epizyme, Inc.. Pursuant to the transaction, Ipsen (IPSEF) acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right of $1.00 per share.
Captura Biopharma revolutionizes treatment for catastrophic emergency internal transuranic radiation contamination and heavy metal poisoning NEW YORK---- Captura Biopharma, an emerging biotechnology company developing and commercializing oral chelators to treat internal transuranic radionuclide contamination and heavy metal poisoning, and OceanTech Acquisitions I Corp. (OTEC), a special purpose acquis...
WAYLAND, Mass. In support of the merger, Disc has secured commitments from a syndicate of healthcare investors led by Access Biotechnology and including OrbiMed, Atlas Venture, 5AM Ventures, Novo Holdings A/S, Arix Bioscience, Rock Springs Capital, and Janus Henderson Investors, for a $53.5 million financing that is expected to close concurrent with the completion of the merger.
Catalent, Inc. (CTLT), the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it has reached an agreement to acquire Metrics Contract Services, a full-service specialty Contract Development and Manufacturing Organization with a facility in Greenville, Nor...
Gilead Will Provide up to $5 Million in Global Grant Funding to Immediately Support Public Education and Vaccine Hesitancy Communications, a Public Policy Response and a Global Outbreak Emergency Fund for Community Organizations in Regions with Active Monkeypox Outbreaks FOSTER CITY, Calif.
TAZVERIK® Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with Ipsen Expected to Close in 3Q 2022 CAMBRIDGE, Mass. “I am pleased with the progress we made as an organization in the second quarter.
Second Quarter 2022 Results: -- Net revenues of $73.9 million, net loss available to common shareholders of $ million and diluted GAAP loss per share of $ -- Lead Rare Disease asset, Purified Cortrophin® Gel 80 U/ml net sales of $10.2 million -- -- Adjusted non-GAAP EBITDA of $9.9 million and adjusted non-GAAP diluted earnings per share of $0.13 -- -- Year-over-year net revenue growth of 52% ...
Regulatory News: Ipsen S.A. (IPSEF) today announced that Hibernia Merger Sub, Inc., its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock of Epizyme (EPZM), Inc. at a price of $1.45 per share, to the holder in cash, without interest and less applicable withholding taxes, plus one non...
Acquisition Provides Gilead with MiroBios Pipeline of Immune Checkpoint Agonists and Proprietary Discovery Platform MiroBios Scientific Approach to Restoring Immune Balance for the Treatment of Autoimmune Diseases Complements Gileads Inflammation Research and Development Strategy FOSTER CITY, Calif. This press release features multimedia.
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.
PDF’s require Adobe® Reader® and will open in a new window.
Log In Required
Line of Credit Log In Required